🧠 Neuralink’s Brain Chip Technology Backed by Elon Musk

🧍‍♀️ Who is Audrey Crews?

Audrey Crews, identified publicly as Patient 9 (P9), is the first female recipient of Neuralink’s brain–computer interface (BCI).
Paralyzed for 20 years, she underwent surgery at the University of Miami Health Center earlier in July 2025. She had 128 ultra-thin electrode threads implanted into her motor cortex.
Following the procedure, Crews successfully typed her name, played games, and drew on a computer using only her thoughts. She posted about the experience online, sharing: “I tried writing my name for the first time in 20 years. I’m working on it. Lol.”
Elon Musk acknowledged her accomplishment on X (formerly Twitter), emphasizing its significance and responding: “She is controlling her computer just by thinking. Most people don’t realise this is possible.”

Founded by Elon Musk in 2016, Neuralink is a neurotechnology company developing implantable devices to link human brains with computers. Its long-term vision includes treating neurological disorders and enabling human–AI symbiosis.
The U.S. FDA granted clinical trial approval in May 2023, permitting human testing after initial safety concerns in 2022.

At its core is a small device called the N1 Implant, also referred to as The Link or product name Telepathy. It consists of a coin‑sized chip plus strands of ultra-flexible wires (“threads”).
The device can host over 1,000 electrodes—some reports say up to 3,072—spread across 128 to 1,024 electrode threads. They are just microns thick, minimizing brain damage and improving biocompatibility.
A robotic inserter precisely places these threads into the brain tissue, avoiding blood vessels while reducing surgical trauma.
The implant contains custom-designed ASIC electronics with analog-to-digital converters and wireless telemetry. A small battery enables inductive charging. Neural signals are sent to external devices and decoded via algorithms into commands.

Neuralink aims first to help individuals with paralysis, ALS, Parkinson’s disease, blindness, and spinal cord injuries by enabling neural signal–based control of computers and prosthetics.
The Blindsight project—designed to restore vision by bypassing the optic nerve and directly stimulating the visual cortex—received FDA Breakthrough Device designation in 2024.
The second patient, known as “Alex,” has used the chip to play video games and design 3D CAD models using just thought-based controls.
Noland Arbaugh, Neuralink’s first patient, could control a cursor, browse the web, and compose messages. Nevertheless, about 85% of the implanted threads loosened over time, limiting functionality. Software updates helped restore partial control.

Neuralink plans to scale up to 20,000 implant procedures per year and generate ~$1 billion in annual revenue by 2031. It will offer three product versions:
- Telepathy (brain-machine interface)
- Blindsight (vision restoration)
- Deep (treatment for movement disorders like Parkinson’s, tremors)
The company has already performed nine human implant surgeries, including performing two in one day.

Technical issues: implant longevity and electrode migration are notable concerns (e.g. detached threads).
Animal welfare controversies: critics such as PETA and PCRM have flagged Neuralink for causing harm in pig and monkey testing.
Ethical risks: data privacy of neural information, societal inequality, and futuristic claims like telepathy or memory replay raise concerns

Feature	Description
Audrey Crews (P9)	First female Neuralink recipient; regained ability to type and draw via thought after 20 years of paralysis.
Neuralink N1 Implant	Coin-sized device with ultra-thin electrode threads; inserted robotically into motor cortex.
Core Capabilities	Reads neural signals via electrodes → wirelessly sends data → AI decodes into digital actions.
Target Applications	Assist individuals with paralysis, vision loss (Blindsight), motor diseases.
Milestones	First implant in human (Jan 2024); two surgeries in one day; nine total as of mid‑2025.
Challenges	Long-term reliability, surgical risk, ethical and privacy concerns.
Vi